Red Light Therapy for Depression: Evidence Review

Depression is one of the leading causes of disability worldwide, and in the United Kingdom alone, approximately one in six adults experiences a common mental health disorder in any given week. Standard treatments, primarily antidepressant medication and psychotherapy, help many people but leave a substantial number with residual symptoms or intolerable side effects. This has driven interest in adjunctive treatments, and transcranial photobiomodulation (tPBM) using near-infrared light has emerged as one of the more intriguing candidates.

This article examines the clinical evidence for using red and near-infrared light therapy as a treatment for depression, explains the proposed biological mechanisms, and provides practical guidance for anyone considering this approach.

What Is Transcranial Photobiomodulation?

Transcranial photobiomodulation (tPBM) involves applying near-infrared (NIR) light, typically at wavelengths between 808 nm and 850 nm, to the scalp and forehead. At these wavelengths, photons penetrate the skull and reach the outer layers of the cerebral cortex, a depth of approximately 2-3 cm from the scalp surface (Tedford et al., 2015, Lasers in Surgery and Medicine).

This is distinct from bright light therapy used for seasonal affective disorder (SAD), which works through the eyes and the retino-hypothalamic pathway to regulate circadian rhythms. tPBM works directly on brain tissue, targeting mitochondrial function in cortical neurons.

The distinction matters because it means tPBM may address depression through entirely different mechanisms than bright light boxes, making it potentially relevant for non-seasonal depression as well.

The Biological Mechanism

Mitochondrial Dysfunction in Depression

A growing body of evidence links depression to impaired mitochondrial function in the brain, particularly in the prefrontal cortex (PFC). The PFC is responsible for executive function, emotional regulation, and mood, and neuroimaging studies consistently show reduced metabolic activity (hypometabolism) in the PFC of depressed individuals (Koenigs & Grafman, 2009, Neuroscience & Biobehavioral Reviews).

Mitochondrial dysfunction in depression manifests as:

• Reduced ATP production in cortical neurons, leading to diminished neural activity
• Elevated oxidative stress from inefficient electron transport chain function
• Impaired neuroplasticity due to insufficient energy for synaptic remodelling
• Altered calcium signalling affecting neurotransmitter release and receptor sensitivity

How NIR Light Addresses This

Near-infrared light at 810-850 nm is absorbed by cytochrome c oxidase (CCO), the terminal enzyme in the mitochondrial electron transport chain. When CCO absorbs NIR photons, several things happen:

1. Nitric oxide dissociation. NO is displaced from the CCO binding site, restoring normal electron flow and increasing ATP production (Karu, 2008, Photochemistry and Photobiology).
2. Brief ROS signalling. A transient, mild increase in reactive oxygen species activates Nrf2, upregulating endogenous antioxidant defences and reducing the chronic oxidative stress associated with depression (Hamblin, 2018, BBA Clinical).
3. Increased cerebral blood flow. NIR light causes local vasodilation through NO-mediated pathways, improving oxygen and nutrient delivery to hypometabolic regions (Tian et al., 2016, Neurophotonics).
4. BDNF upregulation. Brain-derived neurotrophic factor, essential for neuroplasticity and neuronal survival, is increased following tPBM (Xuan et al., 2015, Journal of Biophotonics).

Effects on Neurotransmitter Systems

The downstream effects on neurotransmitter function are particularly relevant to depression:

• Serotonin. Enhanced mitochondrial function in serotonergic neurons of the dorsal raphe nucleus (which projects to the PFC) may increase serotonin synthesis and release. ATP is required for tryptophan hydroxylase activity, the rate-limiting enzyme in serotonin production.
• Dopamine. Similar ATP-dependent mechanisms apply to dopamine synthesis in the ventral tegmental area. Anhedonia, a core feature of depression, is linked to dopaminergic dysfunction.
• Glutamate/GABA balance. Mitochondrial function influences the glutamate-glutamine cycle and GABA synthesis, both of which are disrupted in depression.
• Noradrenaline. Improved energy metabolism in the locus coeruleus may support noradrenergic function, relevant to the fatigue and concentration difficulties seen in depression.

Key Clinical Studies

Schiffer et al. (2009) — The First Controlled Trial

The landmark study by Schiffer and colleagues at Harvard Medical School was the first controlled trial of tPBM for depression, published in Behavioural and Brain Functions.

Design: Randomised, double-blind, placebo-controlled. Ten patients with major depressive disorder received a single session of NIR light (810 nm, 250 mW/cm2, 60 J/cm2) applied to the forehead bilaterally, targeting the left and right dorsolateral prefrontal cortex (DLPFC). Controls received sham treatment.

Results:

• Significant improvements in Hamilton Depression Rating Scale (HAM-D) scores at 2 weeks post-treatment in the active group compared to sham
• Significant improvements in Hamilton Anxiety Rating Scale (HAM-A) scores
• No adverse effects reported
• Improvements were evident from a single treatment session

Limitations: Small sample size (n=10). However, this study provided proof of concept that NIR light could penetrate the skull in sufficient quantities to produce measurable clinical effects.

Cassano et al. (2015) — Open-Label Dose-Finding

Cassano and colleagues at Massachusetts General Hospital published an open-label study in Photomedicine and Laser Surgery examining repeated tPBM sessions for depression.

Design: Open-label, 12 patients with major depressive disorder. Participants received NIR light (808 nm, 700 mW/cm2 at the LED, estimated 36 mW/cm2 at the cortical surface) applied to the forehead and temporal areas. Treatment consisted of two sessions per week for six weeks (12 sessions total).

Results:

• Mean HAM-D score decreased from 19.8 (moderate depression) to 13.0 (mild depression)
• 6 of 12 participants (50%) met criteria for treatment response (>50% reduction in HAM-D)
• 4 of 12 participants (33%) achieved remission (HAM-D less than or equal to 7)
• Significant improvements in anxiety measures
• Improvements in cognitive function, particularly executive function tasks

Limitations: No control group (open-label design). Results could reflect placebo response, natural fluctuation, or regression to the mean. However, the magnitude of improvement and the consistency across multiple outcome measures are noteworthy.

Cassano et al. (2018) — Randomised Controlled Trial

The same group followed up with a more rigorous randomised controlled trial published in Psychological Medicine.

Design: Randomised, double-blind, sham-controlled. Twenty-one patients with major depressive disorder received either active tPBM (808 nm) or sham treatment, delivered twice weekly for eight weeks (16 sessions), targeting bilateral DLPFC and bilateral frontal poles.

Results:

• The active tPBM group showed significantly greater improvements in HAM-D scores compared to sham
• Response rates were higher in the active group
• Functional near-infrared spectroscopy (fNIRS) confirmed increased cerebral blood flow and oxygenation in the PFC following active treatment
• No serious adverse events

This study provided the strongest evidence to date that tPBM has genuine antidepressant effects beyond placebo, with objective neuroimaging confirmation of the proposed mechanism.

Disner et al. (2016) — Cognitive Effects

Disner and colleagues published a study in the Journal of Affective Disorders examining the effects of tPBM on cognitive-emotional processing in depression.

Design: Randomised, controlled. Participants with elevated depressive symptoms received either active tPBM (1064 nm) or sham, applied to the right forehead.

Results:

• Active treatment produced significant changes in attention bias, with reduced attention to negative stimuli and increased attention to positive stimuli
• These changes in cognitive-emotional processing are consistent with antidepressant effects
• Effects were measured using the dot-probe task, a validated measure of attention bias

This study is significant because it demonstrates that tPBM can modify the negative cognitive bias that is a hallmark of depression, suggesting the mechanism goes beyond simple metabolic enhancement.

Ongoing Research

Several larger trials are currently underway or recently completed, including:

• A multi-site RCT by Cassano’s group with a larger sample size
• Studies examining tPBM as an adjunct to antidepressant medication
• Trials combining tPBM with cognitive behavioural therapy (CBT)
• Studies using different wavelengths (810 nm vs 850 nm vs 1064 nm) and application sites

Seasonal Affective Disorder (SAD)

SAD affects approximately 3% of the UK population, with a further 10-15% experiencing sub-syndromal seasonal symptoms. The established treatment is bright light therapy (10,000 lux white light) delivered through the eyes, which works by suppressing melatonin and resetting the circadian clock.

tPBM may offer an additional or alternative approach for SAD through different mechanisms:

• Direct cortical effects. By addressing PFC hypometabolism, tPBM may improve mood independently of circadian rhythm correction.
• Combined approach. Using bright light therapy in the morning (for circadian effects) alongside tPBM (for cortical metabolic effects) may produce additive benefits.
• For SAD patients who find bright light therapy insufficient. Some people respond partially to bright light but continue to experience depressive symptoms. tPBM may address the residual depression.

It is important to note, however, that tPBM has not been specifically studied in SAD populations, so this application remains theoretical, albeit biologically plausible.

Treatment Protocol for Depression

The following protocol is based on the parameters used in the clinical studies described above.

Wavelength

• Primary: 810-850 nm (near-infrared). This is the wavelength range used in the majority of depression studies.
• Alternative: 1064 nm (used by Disner et al.). This longer wavelength may penetrate slightly deeper but has less evidence specifically for depression.
• Red light (630-660 nm) alone is insufficient for transcranial application. Red wavelengths do not penetrate the skull effectively. NIR is essential.

Application Site

• Primary targets: Left and right dorsolateral prefrontal cortex (DLPFC), roughly corresponding to the forehead 2-3 cm above the outer edge of each eyebrow.
• Additional targets: Frontal poles (centre of forehead), temporal regions (temples).
• The light source should be placed directly against the forehead or within 1-2 cm of the skin to maximise transcranial penetration.

Dosing

Parameter	Value
Wavelength	810-850 nm
Irradiance at scalp	200-700 mW/cm2 (device-dependent)
Treatment time per site	3-6 minutes
Total session time	12-20 minutes (covering 4 sites)
Energy density	20-60 J/cm2 per site
Frequency	2-3 sessions per week
Minimum trial period	6-8 weeks

Practical Steps

1. Cleanse the forehead. Remove any makeup, sunscreen, or skincare products that could reduce light penetration.
2. Part the hair if treating temporal areas. Hair significantly reduces NIR transmission. For forehead treatment, this is usually not an issue.
3. Position the device. Hold or mount the light source directly against or very close to each treatment site.
4. Treat each site for 3-6 minutes. Left DLPFC, right DLPFC, left temporal, right temporal, or centre forehead.
5. Close your eyes during treatment but do not wear opaque goggles that cover the forehead (they would block the light from reaching the target area). If using a full-body panel, you may direct the panel at your forehead from a distance of 15-30 cm for a longer duration (15-20 minutes) to compensate for the reduced irradiance at distance.
6. Be consistent. The clinical studies showing benefit used regular protocols over 6-8 weeks.

Device Options for tPBM

Not every red light therapy device is suitable for transcranial photobiomodulation. The key requirements are:

Dedicated tPBM Devices

Several devices have been designed specifically for transcranial application:

• Vielight Neuro Duo — 810 nm, intranasal + transcranial. Designed specifically for brain applications with published clinical data. Premium price (approximately £1,200-1,500) but the most evidence-backed option.
• Vielight Neuro Gamma — 810 nm, 40 Hz pulsed. Designed for cognitive applications, with specific evidence in Alzheimer’s and cognitive decline. Also used in depression research.

Panel Devices (Adapted Use)

Full-body or half-body panels can be used for transcranial application, but with important considerations:

• The panel must include 810 nm or 850 nm wavelengths
• Position close to the forehead (15-30 cm) for adequate irradiance
• Longer treatment times are needed to compensate for the greater distance compared to direct-contact devices
• This approach delivers NIR to a broader area but with lower per-point irradiance

Suitable panels include the Mito Red MitoPRO series (850 nm), PlatinumLED BioMax (810 nm + 850 nm), and Joovv (850 nm).

What to Avoid

• Red-only devices (630-660 nm). These wavelengths do not penetrate the skull sufficiently.
• LED face masks. Most deliver very low irradiance (5-20 mW/cm2) and emit primarily red light. Insufficient for transcranial effects.
• Devices without verified wavelength specifications. For brain applications, the correct wavelength is critical.

Comparison to Conventional Treatment

tPBM should not be viewed as a replacement for established depression treatments, but understanding its position relative to them is useful.

Antidepressant Medication

• SSRIs/SNRIs have extensive evidence (hundreds of RCTs) and remain the first-line pharmacological treatment
• Typical response rate: 50-60% for first-line SSRI
• Side effects: Sexual dysfunction (30-70%), weight gain, emotional blunting, discontinuation syndrome
• tPBM by contrast: Minimal side effects, no systemic drug interactions, but far less evidence (small trials only)

Psychotherapy (CBT)

• CBT has strong evidence for mild-to-moderate depression
• Response rate: 40-60%
• No physical side effects but requires trained therapists, regular sessions, and active engagement
• tPBM could potentially be used alongside CBT as an adjunctive treatment

Electroconvulsive Therapy (ECT)

• ECT is reserved for severe, treatment-resistant depression
• Response rate: 50-70% in treatment-resistant cases
• Side effects: Memory impairment, requires general anaesthesia
• tPBM is being investigated for treatment-resistant depression but currently has no evidence in this specific population

Transcranial Magnetic Stimulation (TMS)

• rTMS is the closest comparator to tPBM in terms of mechanism (both target the DLPFC)
• FDA-cleared for treatment-resistant depression
• Response rate: 50-60%
• Cost: £3,000-5,000 per course, requires clinic attendance
• tPBM targets similar brain regions, is far cheaper, and can be self-administered at home, but has much less evidence

Safety and Cautions

Known Side Effects

Side effects from tPBM in the published studies have been minimal:

• Mild headache (reported in approximately 5% of participants, typically resolving within hours)
• Transient dizziness in rare cases
• No serious adverse events in any published trial

Who Should Avoid tPBM for Depression

• Anyone with active suicidal ideation should seek immediate professional help. tPBM is not appropriate as a sole treatment for severe depression.
• People with photosensitive epilepsy should avoid pulsed NIR, particularly at frequencies that could trigger seizures.
• Patients on lithium should consult their psychiatrist, as lithium has been shown to enhance photobiomodulation effects, and dosing adjustments may theoretically be needed.
• Those with active brain tumours or lesions should avoid transcranial light application until more safety data is available.

Important Perspective

The evidence for tPBM in depression, whilst mechanistically compelling and supported by several positive trials, remains limited in terms of sample sizes and replication. No national treatment guideline currently recommends tPBM for depression. It is best viewed as a promising experimental adjunct rather than an established treatment.

If you are currently taking antidepressant medication, do not stop or reduce your dose based on starting tPBM. Any medication changes should be made under medical supervision.

Frequently Asked Questions

Is this the same as a SAD lamp?

No. SAD lamps (bright light therapy) work through the eyes to reset circadian rhythms. tPBM uses near-infrared light applied to the forehead to directly affect brain mitochondrial function. They work through entirely different mechanisms and can potentially be used together.

How long before I notice an effect?

The clinical studies showed statistically significant improvements after 4-8 weeks of regular treatment (2-3 sessions per week). Some participants reported subjective improvements earlier, but a minimum of 6 weeks of consistent use is advisable before assessing results.

Can I use a red light panel I already own?

Possibly, if it includes 810 nm or 850 nm wavelengths and delivers adequate irradiance (at least 50 mW/cm2 at forehead distance). Red-only panels (660 nm) are not suitable for transcranial application.

Is tPBM safe long-term?

No long-term safety studies exist, but the mechanism of action (enhancing normal mitochondrial function) does not suggest cumulative risk. The wavelengths used do not cause DNA damage or thermal injury at therapeutic doses. Several research groups have used tPBM for extended periods (months to years) in ongoing studies without reported adverse events.

Can children or teenagers use tPBM for depression?

There are no published studies of tPBM for depression in young people. Given the ongoing brain development in this age group, professional guidance should be sought before considering tPBM for anyone under 18.

The Bottom Line

Transcranial photobiomodulation for depression is one of the more scientifically grounded emerging treatments in the mental health space. The mechanism is well-characterised (CCO absorption, ATP enhancement, cerebral blood flow increase, BDNF upregulation), the clinical trials are consistently positive (albeit small), and the safety profile is excellent.

It is not yet ready to be recommended as a standalone treatment for depression. The evidence base is simply too small. But as an adjunct to conventional treatment, for people who want to explore every reasonable avenue, tPBM represents a low-risk option with a plausible biological rationale and encouraging preliminary data.

The most critical practical consideration is ensuring you use near-infrared wavelengths (810-850 nm) applied directly to the forehead, not red light through a face mask or from across the room. The physics of transcranial penetration demand the right wavelength at adequate irradiance, delivered close to the scalp.

---

This article is for informational purposes only and does not constitute medical advice. Depression is a serious condition. If you are experiencing depression, please consult a qualified healthcare professional. If you are in crisis, contact the Samaritans on 116 123 or text SHOUT to 85258.